Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).

被引：5
|
作者：
Sayala, Hazem A.
Moreton, Paul
Jones, Richard A.
Rawstron, Andy C.
O'Connor, Sheila J.
Evans, Paul
Anthony, Carter
Dearden, Claire
Matutes, Estella
Pettitt, Andrew R.
Kennedy, Daniel B.
Hillmen, Peter
机构：
[1] Leeds Gen Infirm, Haematol Malignacy Diag Serv, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
[3] Canc Res Inst, London, England
[4] Leicester Royal Infirm, Leicester, Leics, England
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.34.34
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
34
引用
收藏
页码：14A / 15A
页数：2
相关论文
共 50 条
  • [1] Interim report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, H
    Moreton, P
    Richard, JA
    Andy, RC
    Sheila, O
    Paul, E
    Anthony, C
    Claire, D
    Estella, M
    Andrew, PR
    Daniel, KB
    Peter, H
    BLOOD, 2005, 106 (11) : 599A - 600A
  • [2] Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)
    Sayala, HA
    Moreton, P
    Jones, RA
    Rawstron, AC
    O'Connor, SJ
    Evans, P
    Carter, A
    Dearden, C
    Matutes, E
    Pettitt, AR
    Kennedy, DB
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 3 - 3
  • [3] Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire E.
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Barrans, Sharon
    Worrillow, Lisa
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 407 - 408
  • [4] Report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab and fluclarabine in patients with fluclarabine refractory CLL (on behalf of the NCRI CLL trials sub-group)
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A. C.
    O'Connor, S. J.
    Evans, P. E.
    Carter, A.
    Dearden, C.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, B. D.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 3 - 3
  • [5] Long term survival report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory chronic lymphocytic leukaemia
    Varghese, A. M.
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A.
    O'Connor, S. J.
    Evans, P.
    Anthony, C.
    Dearden, C. E.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, D. B.
    Barrans, S.
    Worrillow, L.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 46 - 46
  • [6] NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Cohen, Dena
    Pocock, Christopher F. E.
    Rawstron, Andy
    Gregory, Walter M.
    Smith, Alex
    Skinner, Emma
    Critchley, Anne
    Milligan, Donald
    Dearden, Claire E.
    McCarthy, Helen
    Fegan, Chris
    Follows, George A.
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 33 - 34
  • [7] NCRN CLL207 study of alemtuzumab consolidation in chronic lymphocytic leukaemia: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group)
    Varghese, A. M.
    Cohen, D.
    Pocock, C. F. E.
    Rawstron, A.
    Gregory, W. M.
    Smith, A.
    Skinner, E.
    Critchley, A.
    Milligan, D.
    Dearden, C. E.
    McCarthy, H.
    Fegan, C.
    Follows, G. A.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 8 - 8
  • [8] Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Groner, Sija
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Ulrich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Truemper, Lorenz H.
    Soeling, Ulrike
    Schlag, Rudolf
    Hallek, Michael
    Doehner, Hartmut
    BLOOD, 2008, 112 (11) : 127 - 127
  • [9] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Ritgen, Matthias
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 1087 - 1087
  • [10] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
12345